approximation of ''the truth,'' as indicated by item (1) . As with most studies employing the Surveillance, Epidemiology, and End Results database of the National Cancer Institute, information is limited regarding the scope of the intended surgical procedure and pathology quality control. While these are indeed major shortcomings, our hope is to offset this by dramatically increasing patient sample size to diminish the effect of random errors.
We agree with Dr. Metze about the potential for bias introduced during pathological analysis, but we have no practical way of proving this, nor of determining if this is a bias introduced at all centers (systematic error) or only at select centers (random error). It is instructive to point out, however, that Dr. Metze's theory of pathological bias is based on the assumption that the examining pathologist will preferentially harvest macroscopically apparent lymph nodes. Such nodes would seem more likely to harbor metastases than their smaller and more troublesome to identify counterparts. However, there is little information to suggest that presence on metastatic disease in lymph nodes can be judged on size criteria alone. In fact, the ability to determine the metastatic status of a lymph node basin based on inspection and palpation is little better than a flip of a coin. 2 Thus, one must assume that pathologists must fail to harvest negative lymph nodes with a similar frequency to positive lymph nodes. Even if we concede the unlikely scenario that only negative lymph nodes will go unharvested, Dr. Metze's data set aligns with our published results. Although LNY achieved significance as a prognostic factor in the univariate analysis of our patient population as a whole, we were not able to demonstrate an understaging effect in node-negative medullary thyroid cancer patients by univariate or multivariate analysis. As Dr. Metze himself asserts, ''the absence of this effect in node-negative patients suggests that nodal understaging is unlikely to be an important problem … because the relation between LNY and improved survival should not be restricted to the subgroup with metastases.'' 1 Indeed, we agree that the only group that we can use to demonstrate nodal understaging is the node-negative population. If we repeat Dr. Metze's analysis using his test data set, but restrict our observations to the node-negative population (n = 16), then both LNpathologist and LNspecimen are no longer prognostic factors (p [ 0.2 and p [ 0.2, respectively), as we noted in our study.
Again, we are in agreement with Dr. Metze that pathology sampling bias may exist in our study, but that it is difficult to prove or disprove given the constraints of our registry data. Furthermore, we welcome his call for prospective investigations with standardized histopathology protocols to further assess this important issue. 
